Patents by Inventor Doris Apt
Doris Apt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160151478Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.Type: ApplicationFiled: November 16, 2015Publication date: June 2, 2016Inventors: Doris Apt, Juha Punnonen, Alice M. Brinkman
-
Patent number: 9186397Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.Type: GrantFiled: March 11, 2014Date of Patent: November 17, 2015Assignee: Altravax, Inc.Inventors: Doris Apt, Juha Punnonen, Alice M. Brinkman
-
Publication number: 20150290313Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.Type: ApplicationFiled: March 11, 2014Publication date: October 15, 2015Applicant: Altravax, Inc.Inventors: Doris Apt, Juha Punnonen, Alice M. Brinkman
-
Patent number: 8715694Abstract: The invention provides polypeptides and virus-like particles having, for example, an ability to induce an immune response to flaviviruses. The polypeptides can include C15, prM, and E polypeptide sequences.Type: GrantFiled: April 16, 2012Date of Patent: May 6, 2014Assignee: Altravax, Inc.Inventors: Doris Apt, Juha Punnonen, Alice M. Brinkman
-
Publication number: 20120282287Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.Type: ApplicationFiled: April 16, 2012Publication date: November 8, 2012Inventors: Doris Apt, Juha Punnonen, Alice M. Brinkman
-
Patent number: 8168772Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.Type: GrantFiled: August 30, 2007Date of Patent: May 1, 2012Assignee: Altravax, Inc.Inventors: Doris Apt, Juha Punnonen, Alice M. Brinkman
-
Patent number: 8158131Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.Type: GrantFiled: March 7, 2008Date of Patent: April 17, 2012Assignee: AltraVax, Inc.Inventors: Doris Apt, Juha Punnonen, Alice M. Brinkman
-
Publication number: 20100261660Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability of the polypeptides to preferentially bind a CD28 or CTLA-4 receptor at a level greater or less than the ability of human B7-1 to bind CD28 or CTLA-4, or to induce or inhibit altered level of T cell proliferation response greater compared to that generated by human B7-1. The polypeptides and polynucleotides of the invention are useful in therapeutic and prophylactic treatment methods, gene therapy applications, and vaccines.Type: ApplicationFiled: December 22, 2006Publication date: October 14, 2010Applicant: Maxygen, Inc.Inventors: Juha Punnonen, Alexandra Lazetic, Steven R. Leong, Chia-Chun Chang, Doris Apt, Claes Gustafsson
-
Publication number: 20090311287Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.Type: ApplicationFiled: August 30, 2007Publication date: December 17, 2009Applicant: Maxygen, Inc.Inventors: Doris Apt, Juha Punnonen, Alice M. Brinkman
-
Publication number: 20090181044Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.Type: ApplicationFiled: March 7, 2008Publication date: July 16, 2009Inventors: Doris Apt, Juha Punnonen, Alice M. Brinkman
-
Patent number: 7476390Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.Type: GrantFiled: February 26, 2003Date of Patent: January 13, 2009Assignee: Maxygen, Inc.Inventors: Doris Apt, Juha Punnonen, Alice M. Brinkman
-
Publication number: 20060269566Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability of the polypeptides to preferentially bind a CD28 or CTLA-4 receptor at a level greater or less than the ability of human B7-1 to bind CD28 or CTLA-4, or to induce or inhibit altered level of T cell proliferation response greater compared to that generated by human B7-1. The polypeptides and polynucleotides of the invention are useful in therapeutic and prophylactic treatment methods, gene therapy applications, and vaccines.Type: ApplicationFiled: January 13, 2006Publication date: November 30, 2006Applicant: Maxygen, Inc.Inventors: Juha Punnonen, Alexandra Lazetic, Steven Leong, Chia-Chun Chang, Doris Apt, Claes Gustafsson
-
Publication number: 20050154189Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability of the polypeptides to preferentially bind a human CD28 or CTLA-4 receptor at a level greater or less than the ability of human B7-1 to bind human CD28 or CTLA-4, or to induce or inhibit altered level of T cell proliferation response greater compared to that generated by human B7-1. The polypeptides and polynucleotides of the invention are useful in therapeutic and prophylactic treatment methods, gene therapy applications, and vaccines.Type: ApplicationFiled: June 21, 2002Publication date: July 14, 2005Inventors: Juha Punnonen, Alexandra Lazetic, Steven Leong, Jean Chang, Doris Apt, Claes Gustafsson
-
Publication number: 20050084913Abstract: The invention provides novel polypeptides, including novel tumor-associated antigens, and related nucleic acids, vectors, cells, and antibodies. The invention also provides compositions comprising such polypeptides, nucleic acids, vectors, cells, and antibodies, and methods of producing and using the same.Type: ApplicationFiled: April 19, 2004Publication date: April 21, 2005Inventors: Juha Punnonen, Doris Apt, Margaret Neighbors, Steven Leong
-
Publication number: 20040110295Abstract: The invention relates to nucleic acid vectors useful for expression and production of polypeptides, compositions comprising vectors, and methods for the production and use of vectors and polypeptides.Type: ApplicationFiled: May 28, 2003Publication date: June 10, 2004Applicant: Maxygen, Inc., a Delaware corporationInventors: Juha Punnonen, Doris Apt, Robert G. Whalen
-
Publication number: 20040009469Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.Type: ApplicationFiled: February 26, 2003Publication date: January 15, 2004Applicant: Maxygen, Inc. Patent DepartmentInventors: Doris Apt, Juha Punnonen, Alice M. Brinkman
-
Publication number: 20030190697Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability of the polypeptides to preferentially bind a CD28 or CTLA-4 receptor at a level greater or less than the ability of human B7-1 to bind CD28 or CTLA-4, or to induce or inhibit altered level of T cell proliferation response greater compared to that generated by human B7-1. The polypeptides and polynucleotides of the invention are useful in therapeutic and prophylactic treatment methods, gene therapy applications, and vaccines.Type: ApplicationFiled: June 22, 2001Publication date: October 9, 2003Inventors: Juha Punnonen, Alexandra L.L. Lazetic, Steven R. Leong, Chia-Chun Jean Chang, Doris Apt, Claes Gustafsson
-
Publication number: 20030138881Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability of the polypeptides to preferentially bind a CD28 or CTLA-4 receptor at a level greater or less than the ability of human B7-1 to bind CD28 or CTLA-4, or to induce or inhibit altered level of T cell proliferation response greater compared to that generated by human B7-1. The polypeptides and polynucleotides of the invention are useful in therapeutic and prophylactic treatment methods, gene therapy applications, and vaccines.Type: ApplicationFiled: December 20, 2001Publication date: July 24, 2003Applicant: Maxygen, Inc.Inventors: Juha Punnonen, Alexandra Lazetic, Steven R. Leong, Chia-Chun Chang, Doris Apt, Claes Gustafsson
-
Patent number: 6399383Abstract: The invention provides human papillomavirus vectors useful in gene therapy. Such a vector contains E1 and E2 coding regions from a benign or low-risk human papillomavirus operably linked to a promoter and enhancer, and an LCR region from a human papillomavirus comprising an origin of replication including binding sites for the E1 and E2 proteins. The invention further provides methods of using such vectors in gene therapy, methods of controlling expression using a patch, and methods of using such vectors to evolve drugs for stimulation of hair growth or alteration of hair color.Type: GrantFiled: October 27, 1998Date of Patent: June 4, 2002Assignee: Maxygen, Inc.Inventors: Doris Apt, Paul Khavari, William P. C Stemmer